Becla (2020): Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries, Journal of Dermatological Treatment,

considered (V, 2018). RESULTS: A total of 10,777 patients were estimated to receive biologics or apremilast in the first model year. Increased penetration of apremilast resulted in an estimated reduction of the total budget by 28.6%, leading to costsavings of V31,606,416 over 5 years (V527,470,278 vs V495,863,863). Total costs per patient decreased by V2,374 over the same time period. The model yielded average annual cost-savings of 5.7% compared to the current treatment scenario. The sensitivity analyses confirmed the robustness of the model results.